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Causes and Consequences of Deviation from
Multidisciplinary Care in Thoracic Oncology
Raymond U. Osarogiagbon, MBBS,* Gregory Phelps, MD,† Joshua McFarlane, MD,‡
and Olufunsho Bankole, MBBS§
Background: Multidisciplinary decision making is advocated in
thoracic oncology because of the multiplicity of management op-
tions. This approach is difficult to implement, and its benefits are
empirical and likely depend on compliance with recommendations.
We evaluated patient outcomes after discussion in a multidisci-
plinary thoracic oncology conference (MTOC).
Methods: Retrospective review of all cases presented at a weekly
MTOC from February 1, 2006 to October 30, 2009. Patients were
separated into cohorts based on concordance between MTOC rec-
ommendations and actual clinical care. Patient characteristics,
MTOC recommendations, clinical care, and outcomes were com-
pared between the two cohorts using appropriate statistical methods.
Results: Three hundred seventy-six patients were discussed at
MTOC, and 454 sets of recommendations were made. Thirty-seven
percent of patients received discordant care. Health insurance status
and race were the only demographic factors significantly associated
with receipt of discordant care. The likelihood of concordance with
specific recommendations varied significantly. Patients who re-
ceived concordant care had significantly shorter delay to onset of
definitive therapy (p  0.002), longer overall (p  0.004), and
progression-free survival (p 0.02). The stage-adjusted hazard ratio
for overall and progression-free survival in the concordant care
cohort was 1.7 and 1.4, respectively. Sixty percent of all discordant
care could be attributed to clinicians’ decision.
Conclusions: Deviation from multidisciplinary recommendations
may be associated with significantly worse outcomes in patients
discussed in an MTOC. Further investigation into the causes of
discordant care is warranted.
Key Words: Quality of care, Multidisciplinary care, Lung cancer,
Survival.
(J Thorac Oncol. 2011;6: 510–516)
Optimal care of patients with lung cancer and otherthoracic tumors requires the active involvement of many
specialists, including radiologists, pulmonologists, thoracic
surgeons, pathologists, medical, and radiation oncologists.
Each specialist brings a particular perspective and skill set to
the diagnosis, staging, and treatment of thoracic tumors.
Distinguishing between benign and malignant lesions, and
choosing the most effective means of management require
interaction between the key specialists. Because of fears that
a system of serial referrals and autonomous decision making
might result in delayed, fragmented, and suboptimal care,1
there has been great interest in formal multidisciplinary fora
where thoracic cases can be discussed and optimal recom-
mendations for treatment made.2
However, the evidence for benefit from multidisci-
plinary care is mostly empirical.3 Yet, setting up multidisci-
plinary programs with the active involvement of the key
specialists is challenging because of the different practice
culture and schedules of the specialists; the need to ensure the
accuracy of clinical information and the appropriateness of
management recommendations; and the need for timely and
accurate communication of recommendations to the respon-
sible clinicians. We hypothesized that if multidisciplinary
recommendations represent the ideal management plan, de-
viation from these recommendations should lead to worse
patient outcomes. If this proves true, it would be necessary to
understand the extent and causes of such deviation and to
devote effort to minimize it.
We evaluated the clinical benefit of our Multidisci-
plinary Thoracic Oncology Conference (MTOC) at the Uni-
versity of Tennessee Cancer Institute by comparing MTOC
recommendations with actual clinical management. We
sought to characterize the extent and etiology of deviations
from recommended care and analyzed the impact on patient
outcomes.
PATIENTS AND METHODS
After approval of our study by the Institutional Review
Board of the University of Tennessee, we reviewed records of
all patients presented for discussion at our MTOC from its
onset in February 2006 to the date of data censorship in
October 2009.
Structure of the MTOC
From February 2006 to February 2007, the MTOC was
held twice a month. After March 2007, the conference was
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held weekly, immediately after a multidisciplinary clinic
(MDC) to facilitate multidisciplinary patient contact before
MTOC patient discussions. Regular participants at the con-
ference included two thoracic surgeons, a radiologist, two
pulmonologists, two medical oncologists, a radiation oncol-
ogist, a palliative care specialist, a nurse coordinator, a nurse
attached to each involved specialty, and a clinical research
coordinator. Pathologists participated on an ad hoc basis,
when a pathology problem was to be discussed. The MDC
consisted of a thoracic surgeon, medical oncologist, pulmo-
nologist, and the MTOC nurse coordinator.
Patient Referral
We created an open referral system, in which providers
could submit patients for discussion in the MTOC. After
creation of the MDC, providers were encouraged (but not
mandated) to have their patients evaluated in the clinic before
discussion. Patients who were not evaluated in the MDC had
to be presented by the referring provider who was, therefore,
an active participant in the clinical care debate. Patients seen
in the MDC were presented by the referring physician or one
of the clinic participants.
MTOC Decision Making and Communication
with Referring Physicians
After conference discussion, consensus recommenda-
tions were enumerated for each patient, and an MTOC note
was placed in each patient’s electronic medical record. In
addition, the nurse coordinator directly contacted each refer-
ring physician with the consensus recommendations within
24 hours, irrespective of the physician’s presence in the
conference. Nevertheless, recommendations were not binding
on the referring physician.
Data Collection
Data on patient demographics, clinical history (includ-
ing performance status, smoking history, histology, and clin-
ical stage), reason for presentation, name of referring and
presenting physician, prior evaluation in the MDC, and man-
agement recommendations of the MTOC were prospectively
recorded on a standardized template. We retrospectively
collected information on actual clinical management and
outcomes from the University of Tennessee Cancer Institute
electronic medical records system, supplemented by a search
of the Social Security Death Index. We abstracted the cause
of discordant care from the medical records.
Statistical Analysis
We compared the recommendations of the MTOC with
the actual clinical care provided. We identified care that
matched recommendations as concordant and mismatched
care as discordant. For statistical reasons, patients who were
presented multiple times were assigned on the basis of com-
pliance with recommendations made at the initial discussion.
We compared the characteristics of patients who received
concordant and discordant care. We also compared outcomes,
including the time to definitive care, overall survival, and
progression-free survival after MTOC discussion.
Categorical variables were compared by the 2 test and
Fisher’s exact test. Survival was estimated by the Kaplan-
Meier method, and survival curves were compared by the
log-rank test. The Cox-proportional hazards model was used
for multiple regression analysis of determinants of survival.
We excluded patients who died or were lost to follow-up
before any clinical intervention from the survival analysis to
avoid bias against the discordant care cohort.
RESULTS
Patients
From February 2006 to October 2009, 376 patients
were presented for discussion at our MTOC. Two hundred
thirty-five patients (63%) received concordant care and 141
(37%) received discordant care. The demographic and clini-
cal characteristics of patients were similar between the
groups, except for race (p 0.05) and health insurance status
(p  0.001) (Table 1). Whites were more likely to receive
TABLE 1. Patient Characteristics





Median age (range), yr 59 (23–92)a 59 (27–84)a 0.6
Sex
Female, 158 (42) 100 (42) 58 (42) 0.9
Male, 218 (58) 136 (58) 81 (58)
Race
Black, 213 (58) 124 (54) 88 (65) 0.04
White, 152 (42) 105 (46) 47 (35)
Insurance
Commercial, 104 (28) 75 (32) 28 (20) 0.001
Medicare, 146 (39) 95 (40) 51 (37)
Medicaid, 61 (16) 38 (16) 23 (17)
None, 65 (17) 27 (11) 37 (27)
Employment status
Employed, 106 (28) 69 (29) 37 (27) 0.16
Retired, 131 (35) 83 (35) 48 (35)
Disabled, 29 (7) 22 (9) 6 (4)
Unemployed, 110 (29) 62 (26) 48 (35)
Performance status
0–1, 352 (94) 222 (94) 130 (93) 0.3
2–4, 24 (6) 14 (6) 10 (7)
Histology
NSCLC, 196 (52) 120 (56) 76 (66) 0.4
SCLC, 14 (4) 10 (5) 4 (3)
Nonlung primary, 87 (23) 58 (27) 29 (25)
Benign, 32 (9) 25 (12) 7 (6)
No diagnosis, 47 (13)
Lung cancer stageb
I, 45 (21) 32 (25) 13 (16)
II, 13 (6) 5 (4) 8 (10)
III, 91 (43) 57 (44) 34 (42)
IV, 61 (29) 35 (27) 26 (32)
a Median (range) age in years.
b Proportion of total cohort of 376.
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
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concordant care than black patients. Those with commercial
insurance were the most likely to receive concordant care and
those with no insurance, least likely. A slight majority of the
uninsured received discordant care (Figure 1). Ninety-four
percent of patients had an Eastern Cooperative Oncology
Group performance status of 0 to 1, and 99% had Eastern
Cooperative Oncology Group 0 to 2.
MDC Attendance
One hundred twenty-eight patients (34% of the whole
cohort) were seen in the MDC before MTOC discussion.
Sixty-five percent of these patients received concordant care,
compared with 61% of those who were not evaluated in the
MDC before their initial presentation.
MTOC Discussions and Recommendations
Four hundred fifty-four sets of recommendations were
made for the 376 patients. Sixty-three patients (17%) were
presented on multiple occasions, with a median of 2 (range:
2–3) discussions. The reasons for discussion in the whole
cohort were advice on options for diagnosis of an intratho-
racic lesion, 147 (32%); advice on first-line treatment for
newly diagnosed cancer, 132 (29%); advice on salvage ther-
apy in patients with progressing or relapsed cancer 74 (16%);
advice on staging newly diagnosed cancer, 48 (11%); advice
on postoperative management options after resection of lung
cancer, 33 (7%); and follow-up discussions of the outcomes
of previously recommended interventions, 19 (4%).
Recommendations were classified into four groups (Ta-
ble 2). Definitive therapy was the most frequent recommen-
dation (49%), followed by biopsy (27%), radiologic studies
(19%), and “other” therapy (6%). The 454 discussions with
recommendations led to 396 identifiable clinical actions.
Fifty-seven discussions (12.6%) did not lead to any identifi-
able clinical activity. We also evaluated the performance of
recommended invasive procedures (Table 3). Fifty invasive
procedure recommendations (22.3%) were not followed by
any identifiable invasive procedures. There were neither glar-
ing differences in the relative proportion of clinical manage-
ment choices (radiologic study, biopsy, treatment, or “other”)
nor in the utilization of invasive tests in the whole cohort
FIGURE 1. Correlation between dis-
cordance and insurance status (2 p
value  0.0009).
TABLE 2. Relative Frequency of Selection of Management
Options by a Panel of Multidisciplinary Experts Compared




N  453 (100%)
Frequency of
Clinical Management,
N  396 (100%)
Radiologic study 85 (18.8) 76 (19.2)
CT scan 43 (9.5) 35 (8.8)
PET/CT scan 39 (8.6) 38 (9.6)
MRI scan 3 (0.7) 3 (0.8)
Biopsy 122 (27) 91 (23)
Diagnostic 66 (14.6) 47 (11.9)
Staging 56 (12.4) 44 (11.1)
Treatment 220 (48.6) 197 (49.8)
Chemotherapy only 75 (16.6) 67 (16.9)
Radiation therapy 7 (1.6) 9 (2.3)
Surgical resection 81 (17.9) 65 (16.4)
Combined modality 57 (12.5) 56 (14.2)
Chemoradiation 49 (10.8) 52 (13.1)
Preoperative
chemotherapy
2 (0.4) 1 (0.3)
Trimodality 6 (1.3) 3 (0.8)
Other 26 (5.7) 31 (7.9)
Continued monitoring 19 (4.2) 25 (6.3)
Hospice care 5 (1.1) 5 (1.3)
Surgical palliation 2 (0.4) 1 (0.3)
CT, computed tomography; PET, positron emission tomography; MRI, magnetic
resonance imaging.
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(Tables 2 and 3). Nevertheless, when we matched the actual
clinical management to the 454 sets of MTOC recommenda-
tions, we observed concordance in only 282 (62%) and
discordance in 171 (38%) cases.
The reason for conference discussion did not seem to
have any impact on the concordance rate of the 376 patients.
However, the concordance rate varied significantly with spe-
cific recommendations overall and also with recommenda-
tions for invasive procedures (Table 4). The highest rates of
concordance occurred with recommendations for radiother-
apy (80%) and radiologic procedures (79%), whereas recom-
mendations for biopsy and combined modality therapy had
the lowest concordance (50%). In the subset of patients with
recommendations involving invasive procedures, recommen-
dations for surgery had the highest concordance rate (68%),
and recommendations for mediastinoscopy (48%) and
“other” procedures (20%) had the lowest.
Outcome of Care
Patients with concordant clinical management had a
significantly shorter time to clinical intervention than those
who received discordant care (median: 14 days versus 25
days, p  0.002). They also had a longer median overall (2.1
years versus 1.3 years, log rank p  0.01) and progression-free
survival (1.3 years versus 0.8 years, log rank p  0.05) than
those who received discordant care (Table 5, Figures 2A, B). In
the Cox proportional hazards model, the hazard ratios for
overall and progression-free survival in the concordant cohort
were 1.8 and 1.5, respectively. These differences in survival
remained significant after adjustment for stage of disease at
the time of presentation (Table 5).
We identified clinician decision as the cause in 104 of
171 (61%) instances of discordant care. Other causes were
patient loss to follow-up care (19%) or refusal of recom-
mended care (15%). In nine instances (5%), the patient died
before the recommended care could be provided. The reasons
for clinician-induced discordance were listed as “clinical
contraindication” in 61, “comorbidity” in 14, “insurance
problem” in 11, “stage discrepancy” in 11, and “poor perfor-
mance status” in seven instances. In most cases, we were
unable to determine the reasons why patients refused recom-
mended care.
DISCUSSION
Many advocate multidisciplinary care for optimal man-
agement of patients with thoracic tumors because of the
complicated sets of clinical decisions involved. Support for
the benefit of this model of care has mostly been based on
intuition and “commonsense,” with little objective evidence
of superior outcomes in patients who participate.3 Superior
outcomes, if achieved, should arise from effective imple-
mentation of multidisciplinary recommendations. We hy-
TABLE 3. Relative Frequency of Recommendation and




N  224 (100%)
Utilization
Frequency,
N  174 (100%)
Endoscopy 39 (17.4) 24 (13.7)
Bronchoscopy 24 (10.7) 18 (10.3)
EBUS/EUS 15 (6.7) 6 (3.4)
Percutaneous biopsy 36 (16) 29 (16.8)
Thoracic surgical operation 134 (60) 106 (60.9)
Mediastinoscopy 32 (14.3) 22 (12.6)
Open thoracotomy 29 (13) 24 (13.8)
Video-assisted
thoracoscopy
70 (31.3) 56 (32.2)
Other thoracic operation 3 (1.4) 4 (2.3)
Other invasive procedure 3 (1.4) 4 (2.3)
EBUS, endobronchial ultrasound; EUS, endoscopic ultrasound.








Reason for initial discussion
Diagnosis 142 (38) 61 39 0.3
Staging 47 (13) 72 28
First-line therapy 113 (30) 57 43
First-line therapy 51 (14) 65 35
Postoperative adjuvant Rx 17 (5) 76 24
Follow-up 6 (2) 83 17
Recommendations
All
X-ray 77 (20) 79 21 0.001
Biopsy 111 (30) 50 50
Combined modality 44 (12) 50 50
Chemotherapy 53 (14) 60 40
Radiotherapy 5 (1) 80 20
Resection 70 (19) 71 29
Other 16 (4) 69 31
Invasive procedures
Endoscopy 35 (18) 49 51 0.02
Percutaneous biopsy 34 (17) 56 44
Mediastinoscopy 29 (15) 48 52
Surgery 88 (45) 68 32
Other 10 (5) 20 80
TABLE 5. Comparison of Survival between Concordance
Groups
Survival All Concordant Discordant p
Median (yr)
OS 2.0 2.1 1.3 0.004
PFS 1.1 1.3 0.8 0.02
Hazard ratio
Unadjusted
OS 1.8 1 0.004
PFS 1.5 1 0.02
Stage adjusted
OS 1.7 1 0.02
PFS 1.4 1 0.04
OS, overall survival; PFS, progression-free survival.
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pothesized that if multidisciplinary recommendations rep-
resent optimal care, deviation from these best-case
recommendations should be associated with demonstrably
inferior outcomes.
One third of patients discussed at our MTOC received
care discordant with recommendations. Health insurance sta-
tus and race were significantly associated with higher rates of
discordant care. Patients who received discordant care had
significant delays in the onset of definitive treatment. They
also had poorer survival. These findings seem to support our
hypothesis that MTOC recommendations reflect optimal
management, and deviation from these recommendations
may lead to inferior treatment. Our study further suggests that
racial minorities and the uninsured still experience health care
disparities, even after gaining access to a comprehensive
multidisciplinary care environment.
We questioned the high proportion of patients receiving
discordant care in our study. Although recommendations
made at MTOC represent ideal proposals for management,
they are not binding on clinicians at the point of care. MTOC
recommendations emphasize histologic staging with a view
to stage-appropriate treatment, careful evaluation of eligibil-
ity for surgical resection, and the use of multimodality ther-
apy for patients with more locally advanced disease.4 These
approaches, which optimize risk stratification and selection
for potentially curative therapy, may not be as readily pur-
sued by clinicians who are not intimately involved in the
MTOC process.5 The cost, risk, and added time required for
FIGURE 2. A, Overall survival by Rec/
Act concordance (yes/no) (log rank p
value  0.0037). B, Progression-free
survival by Rec/Act concordance (log
rank p value 0.0195).
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histologic confirmation of stage, which often entails the use
of highly invasive and specialized techniques, may serve as a
disincentive to clinicians and patients to follow through on
recommendations for these procedures. For example, only
50% of recommendations for mediastinoscopy and 25% of
recommendations for endobronchial ultrasound-guided medi-
astinal lymph node biopsy were carried out. Similarly, con-
cordance was low (50%) with recommendations for com-
bined modality therapy, which improves outcomes in patients
with locally advanced disease but requires coordination be-
tween clinicians from different specialties. This level of
discordance occurred even though these procedures were
available through the specialists involved in the MTOC.
The recommended care may have been inappropriate
for some patients in the discordant care group, for example,
because of inaccurate or incomplete information at the time
of discussion. The referring physicians may have correctly
recognized contraindications to the care proposed by the
MTOC and wisely opted out. Under this theory, the poorer
outcomes of the discordant care group may have been due to
poor patient condition—comorbid illness and poor perfor-
mance status—rather than deviation from optimal care. We
designed the MTOC to foster active participation of the
referring physicians, open discussion, and a consensus deci-
sion-making approach to guard against this possibility.
Our findings are compatible with those of Leo et al.6
who found a trend toward a survival benefit from implement-
ing recommendations of MTOC in their single-year prospec-
tive study of the MTOC process in a region of France.
However, they found a discordance rate of only 5%, com-
pared with 37% in our study. This difference may reflect the
availability of universal health care coverage and the legal
mandate for multidisciplinary care in France, neither of
which exist in the United States. Others have failed to show
any benefit from multidisciplinary care. Riedel et al.,7 in
their study of the Veterans Affairs population, found no
difference in outcomes between an era of MDC care and a
subsequent era without the clinic. However, their clinic did
not involve a thoracic surgeon, and the nonclinic era had
an active MTOC throughout, which probably confounded
their study.
In the absence of demonstrable survival advantage,
some investigators have pointed to surrogate benefits, such as
improved timeliness of care and increased rates of referral for
potentially curative surgery,8 as evidence of benefit from
multidisciplinary programs. Although we found shorter time
from discussion to definitive treatment in those who received
concordant care, it has been pointed out that timeliness of
care for lung cancer does not necessarily translate to im-
proved survival.1,9 It is likely that delays in the discordant
care group were partly due to known and unknown group
characteristics such as poorer insurance status and greater
clinical complexity and may not have been a direct benefit of
the MTOC process itself.
Our study contributes evidence of a quantifiable and
clinically meaningful survival benefit from effective partici-
pation in multidisciplinary care. We demonstrate the need for
quality control measures to ensure that recommendations are
implemented with a high level of fidelity and point to the
need to better understand the reasons for discordant care. The
success of any multidisciplinary program requires provision
of accurate data for discussion, recommendations reflective
of clinically available options, timely communication with
point-of-care clinicians, and effective discussion with pa-
tients regarding the rationale for management plans. Disrup-
tion at any of these levels may cause a deviation from the
recommendations. For example, uninsured patients and their
providers may have no choice but to deviate from recommen-
dations, if there is no realistic avenue to provide access to the
care proposed. Such recommendations, however, “optimal,”
are arguably not reflective of clinically available options for
those particular patients.
The severity of adverse consequences of deviation from
MTOC recommendations may depend on the cause and the
extent of deviation. For example, inability to follow recom-
mendations because of significant unforeseen comorbidities
might not have as much negative impact as inability to follow
recommendations because of lack of insurance coverage or
errors in communicating recommendations or clinician mis-
understanding. We have previously reported our experience
with poor follow-through on recommendations for invasive
procedures during a pilot phase of our MTOC.10 During this
phase, provider failure to carry out recommended procedures
was the main identified cause of discordance. We were able
to reduce this discrepancy in a pilot study of a group clinic
model, in which era the few discrepancies found were due to
patient refusal of recommended interventions.11 We used the
lessons learned to further develop our multidisciplinary pro-
gram in its current form.
The major limitation of our study is the retrospective
design and the absence of a case-mix adjustment between the
concordant and discordant care groups. For example, our
attempt to analyze the reasons for discordance is hampered by
the absence of direct, real-time information. The reasons we
have identified may not be entirely accurate. As an illustra-
tion, although the uninsured made up 17% of the whole
cohort, they contributed 27% of the patients who received
discordant care, but we identified “insurance problem” as the
reason for discordance in only 11 of 171 (6%) instances. We
tried to minimize the adverse effect of retrospective review
by including all patients discussed, by prospectively deter-
mining the data items to be collected, and by standardizing
our data collection tools. Another potential criticism of our
study is the inclusion of all cases discussed, rather than
separation by type of cancer, for example, focusing on the
patients with lung cancer. Nevertheless, this is the reality of
the MTOC experience. All patients with potentially neoplas-
tic intrathoracic pathology are referred for multispecialty
debate and decision making without restriction by specific
diagnosis.
The optimal test of benefit from multidisciplinary care
would entail a prospective comparison between patients re-
ceiving serial specialty care and those receiving care through
a multidisciplinary program. It is possible that our discordant
care cohort was inherently destined for poorer outcomes due
to unidentified health and socioeconomic factors that in
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combination is reflected in the social state of “lack of health
insurance,”12 and the outcome differences we report are not a
result of benefit from multidisciplinary care. A retrospective
study such as this cannot definitively correct for this possibility.
Nevertheless, we can point out the proportional similarity of all
key disease factors such as performance status, histology, and
stage between the two cohorts of patients. In addition, the key
demographic characteristics such as age, sex, and employment
status were similar between the two groups. Only race and
insurance status were significantly different.
Our study suggests the potential for significant clinical
benefits from proper implementation of multidisciplinary
thoracic oncology programs, in which care is taken to max-
imize concordance with best practice recommendations.
Comparative prospective studies of the multidisciplinary tho-
racic oncology process are sorely needed. Such studies will
more accurately quantify the benefits of multidisciplinary
care and delineate the causes of discordant care. Incentives
should be provided to encourage development of effective
multidisciplinary care programs designed to improve the
quality of care provided to patients with tumors of the thorax.
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